Report Highlights

Who Controls This Market — And Who Is Threatening That Control

Moderna's mRNA platform leadership derives not from any single product but from the deepest mRNA development pipeline in the industry — 46 programmes across vaccines, oncology, rare disease, and cardiovascular therapy as of 2024. Moderna's mRNA-1283 next-generation COVID vaccine, RSV vaccine (mResvia, FDA-approved 2024), CMV vaccine (Phase 3), influenza combination vaccine, and personalised cancer vaccine (mRNA-4157/V940 with Merck, Phase 2b) represent the first commercial demonstration that a single mRNA manufacturing and delivery platform can generate multiple regulatory approvals across disease areas. Moderna's competitive moat is its in-house LNP manufacturing and its proprietary NLC (nanostructured lipid carrier) delivery technology, which reduces cold chain requirements versus early-generation LNP formulations.

BioNTech is the mRNA platform holder whose COVID collaboration with Pfizer funded the development of the broadest oncology mRNA pipeline in the industry. BioNTech's individualised neoantigen-specific immunotherapy (iNeST) programme — manufacturing a personalised 34-neoantigen mRNA vaccine for each patient within 6–8 weeks of tumour sequencing — demonstrated 44% reduction in recurrence or death risk in combination with pembrolizumab in the Phase 2b KEYNOTE-942 trial for resected melanoma. BioNTech's pipeline includes mRNA-based autoimmune programmes (BNT111 for autoimmune hepatitis), cancer vaccines, and a BNT162b2 respiratory combination vaccine — the commercial diversification required to sustain revenue as COVID vaccine demand normalises.

Acuitas Therapeutics controls the foundational lipid nanoparticle (LNP) patent portfolio used in both Moderna's and BioNTech's/Pfizer's COVID vaccines under licensing agreements. LNP patents — covering ionisable lipid formulations, lipid ratios, PEGylation chemistry, and manufacturing processes — are the most commercially critical IP in the mRNA delivery space, with Alnylam Pharmaceuticals' LNP patents (used in its siRNA drugs, licensed to Moderna for COVID vaccine) creating parallel IP thickets. Any new mRNA therapeutics entrant must either licence LNP technology from Acuitas/Alnylam, develop alternative delivery technology (lipid-like materials, polymeric NPs, self-amplifying RNA), or risk freedom-to-operate disputes that have already been litigated between Moderna and Arbutus in several jurisdictions.

Industry Snapshot

The mRNA therapeutics market generated approximately USD 14.2 billion in 2024, dominated by COVID vaccine revenues (Moderna's Spikevax and BioNTech's Comirnaty declining from their pandemic peaks but stabilising as annual booster products in endemic phase) and the first commercially launched non-COVID mRNA product (Moderna's mResvia RSV vaccine for adults 60+, approved May 2024). The market structure is in transition: COVID vaccine revenues fell from USD 30+ billion in 2022 to approximately USD 8–10 billion in 2024, while the pipeline of non-COVID mRNA products is advancing toward commercial launches that will begin rebuilding revenue growth in 2026–2030.

The personalised mRNA cancer vaccine segment — despite being pre-revenue — has attracted the most research investment and commercial partnership value of any emerging mRNA application. Moderna and Merck's BNT111-equivalent programme (mRNA-4157/V940) reported Phase 2b data demonstrating 44% improvement in recurrence-free survival for high-risk resected melanoma in combination with pembrolizumab — the first Phase 2b evidence that personalised tumour neoantigen mRNA vaccines improve clinical outcomes beyond checkpoint inhibitor monotherapy. If Phase 3 data (expected 2025–2026) replicates these results, the personalised cancer vaccine market could reach USD 10–20 billion annually by 2034, with each personalised vaccine priced at USD 100,000–250,000 per patient course.

The Forces Accelerating Demand Right Now

The safety and immunogenicity data generated from 13 billion mRNA vaccine doses administered globally in 2021–2023 is the most important dataset in mRNA therapeutics history — providing unprecedented evidence of LNP-mRNA safety, pharmacokinetics, and dose-response relationships across diverse populations, ages, and comorbidity profiles that would have taken 20+ years to generate through normal clinical development. Regulatory agencies (FDA, EMA) have indicated that COVID mRNA platform safety data can be leveraged to reduce Phase 1 safety data requirements for new mRNA vaccines using identical delivery platforms — a 12–18 month development acceleration that reduces Phase 1–2 timelines from 5–7 years to 3–5 years for programmes using the same LNP-mRNA construct as COVID vaccines.

The BioNTech/Pfizer and Moderna/Merck personalised neoantigen cancer vaccine partnerships, each representing USD 1 billion+ in committed Phase 3 development investment, will generate the Phase 3 data (2025–2027 readouts) that determines whether personalised mRNA cancer vaccines become a standard-of-care oncology product at USD 100,000+ per patient or remain a promising but non-standard-of-care option. A positive Phase 3 result in melanoma (highest probability of success given strong Phase 2 data) triggers expansion programmes in lung, bladder, colon, and kidney cancer — expanding the total addressable personalised vaccine market to USD 30–50 billion annually across multiple solid tumour types. The commercial implications are transformative for both Moderna and BioNTech, which have staked their post-COVID commercial models on oncology mRNA revenues.

What Is Holding This Market Back

Current LNP delivery systems preferentially accumulate in the liver following systemic intravenous injection — effective for liver-targeted rare disease programmes (OTC deficiency, alpha-1 antitrypsin deficiency) and for cancer vaccines (where the mRNA is injected intramuscularly and local lymph node antigen presentation is sufficient). For cardiac, lung, muscle, CNS, and tumour-targeted mRNA delivery, tissue-specific LNPs that avoid liver accumulation and preferentially reach the target organ are required. Organ-selective LNP delivery is in active development (Moderna's organ-selective LNPs, Beam Therapeutics' selective organ targeting SORT technology, Precision NanoSystems' microfluidic LNP formulation platforms) but is not yet commercially validated at clinical scale. This delivery barrier limits mRNA therapeutic applications to liver disease, vaccines, and localised injection targets — excluding the largest potential markets of cardiac, muscle, and CNS disease.

mRNA manufacturing requires GMP-grade RNA polymerase, nucleoside triphosphates, capping enzymes, and poly-A polymerases — specialised biochemical inputs with limited supplier diversity, creating supply chain concentration risk. The mRNA molecule itself degrades at ambient temperatures (requiring -70°C cold chain for Moderna's early COVID formulation, -20°C for BioNTech's), creating distribution challenges in low- and middle-income countries with limited cold chain infrastructure. While next-generation LNP formulations are improving stability to 2–8°C refrigerator storage, the manufacturing concentration in North America and Europe creates geographic access inequities that WHO's mRNA Technology Transfer Programme — establishing mRNA manufacturing in South Africa, Indonesia, and Kenya — is working to address with limited commercial scale success to date.

The Investment Case: Bull, Bear, and What Decides It

The bull case is positive Phase 3 data from the Moderna/Merck mRNA-4157/V940 personalised melanoma vaccine programme (readout expected 2025–2026), combined with accelerated FDA Breakthrough Therapy approval and CMS coverage at USD 150,000+ per patient course. Under this scenario, the personalised cancer vaccine indication expands to 5–8 additional solid tumour types by 2030, Moderna and BioNTech achieve combined personalised vaccine revenues of USD 15–25 billion by 2034, and the broader mRNA therapeutics market reaches USD 120–150 billion. Both companies complete their post-COVID revenue rebuilding and achieve consistent profitability. Bull case probability: 30%.

The bear case is Phase 3 personalised cancer vaccine failure (does not replicate Phase 2b results due to patient population expansion from enriched melanoma to broader cancer types), combined with COVID booster revenue declining below USD 3 billion annually by 2027 as global coverage plateaus and competition from protein subunit and self-amplifying mRNA vaccines intensifies. Moderna faces revenue crisis below USD 5 billion annually by 2027 without oncology revenue; BioNTech redirects resources from commercial pipeline to earlier-stage programmes. The mRNA therapeutics market grows but slowly (10%–14% CAGR), driven primarily by infectious disease vaccines for RSV, influenza, and combination seasonal products. Bear case probability: 35%.

The single most important data readout for the mRNA therapeutics market in 2025–2026 is the KEYNOTE-942/mRNA-4157 Phase 3 trial primary endpoint: recurrence-free survival in resected Stage IIB–IV melanoma for personalised mRNA vaccine plus pembrolizumab versus pembrolizumab alone. A positive result (hazard ratio below 0.75 at the pre-specified confidence interval) triggers regulatory filing and commercial launch planning. A negative result (no statistically significant RFS improvement) sends both Moderna and BioNTech's oncology programmes back to Phase 2 for biomarker enrichment strategies and delays the commercial oncology thesis by 3–5 years.

Where the Next USD Billion Is Being Built

The 3–5 year opportunity is mRNA-based vaccines for respiratory combination products — single mRNA constructs encoding antigens for influenza, RSV, SARS-CoV-2, and potentially hMPV and parainfluenza in a single injection. Moderna's mRNA-1230 (influenza + COVID combination), BioNTech's BNT161 respiratory combination programme, and Sanofi's mRNA influenza programme are targeting the USD 8–12 billion annual influenza vaccine market with mRNA platforms that can be updated annually to match circulating strains faster than egg-based manufacturing, providing superior strain match, broader coverage across influenza A subtypes, and potentially superior efficacy in older adults. FDA approval of mRNA combination respiratory vaccines before 2027 creates a USD 5–8 billion near-term commercial opportunity requiring minimal incremental platform investment.

The 5–10 year opportunity is mRNA-based cardiovascular gene therapy — delivering mRNA encoding cardiac proteins lost in heart failure (VEGF-A for angiogenesis, SERCA2a for calcium handling, relaxin for fibrosis) directly to cardiac tissue. Moderna's AZD8601 (VEGF-A mRNA, in collaboration with AstraZeneca) demonstrated improved cardiac function in a Phase 2 trial in heart failure patients with reduced ejection fraction — the first clinical evidence of therapeutic protein delivery to the heart via mRNA. If intramyocardial mRNA delivery (at time of cardiac surgery) achieves Phase 3 success, the total addressable market for mRNA cardiac gene therapy — 64 million heart failure patients globally — represents a multi-tens-of-billions market with no comparable lipid nanoparticle or viral vector gene therapy addressing the same population.

Market at a Glance

Regional Intelligence

The FDA's Center for Biologics Evaluation and Research (CBER) regulates mRNA vaccines and therapeutic biologics under the Biologics License Application (BLA) pathway. The FDA granted Breakthrough Therapy Designation to the Moderna/Merck personalised cancer vaccine programme, accelerating communication with FDA development teams and potentially providing rolling review. The FDA's critical path for mRNA vaccines — established through COVID mRNA vaccine emergency use authorisation and full BLA approval processes (Moderna and BioNTech both achieved full BLA approval in 2021–2022) — provides a regulatory template that reduces review uncertainty for subsequent mRNA vaccine programmes using the same platform architecture. FDA's Project NextGen has allocated USD 5 billion for next-generation COVID vaccine development, with mRNA self-amplifying RNA and pan-coronavirus approaches as primary funded modalities.

The EMA's COVID mRNA vaccine conditional marketing authorisations (granted in December 2020 for BioNTech and January 2021 for Moderna) established the European regulatory precedent for expedited mRNA vaccine review under the PRIME designation and rolling review process. The EMA's Advance Therapy Medicinal Products (ATMP) framework governs mRNA-based gene therapies (as opposed to vaccines), requiring ATMP classification assessment before regulatory review pathway determination. The EMA's Innovation Task Force provides early scientific dialogue for novel mRNA therapeutic modalities, and the EMA's regulatory framework for personalised ATMPs — addressed under the ATMP Regulation 1394/2007 — is being refined through the European Commission's Pharmaceutical Legislation review (proposed 2023) to create clearer adaptive review pathways for personalised medicine products.

Leading Market Participants

• Moderna
• BioNTech
• Pfizer
• CureVac
• Arcturus Therapeutics
• Translate Bio
• Sanofi
• MSD
• Acuitas Therapeutics
• Precision BioSciences

Long-Term Market Perspective

By 2034, mRNA will be an established pharmaceutical modality — not a novel platform but a mature drug development approach with a track record of multiple approved products across vaccine, oncology, and rare disease indications. The market will have 20–35 approved mRNA products globally, compared with four in 2024 (COVID vaccines and RSV). Revenue concentration will have shifted from COVID vaccines (declining) to personalised oncology vaccines (growing), combination respiratory vaccines (stable growth), and the first rare disease mRNA enzyme replacement approvals. The manufacturing infrastructure will have globalised, with mRNA GMP facilities operational in at least 15 countries compared with three in 2022.

The most consequential long-term development is mRNA as a self-amplifying RNA (saRNA) platform — RNA constructs that include a replicase enzyme allowing intracellular amplification of the mRNA signal, requiring 10–100x lower doses than conventional mRNA while producing equivalent protein expression. CSL/Arcturus's STARR technology (self-transcribing and replicating RNA) and VaxEquity (Imperial College spin-out) are the most advanced saRNA platforms, with dose-sparing potential of 10–100x that enables room-temperature stable formulations and multi-antigen constructs previously impossible with conventional mRNA. If saRNA achieves comparable immunogenicity to conventional mRNA at 10x lower dose in Phase 3 trials (first results expected 2025–2027), the manufacturing economics of mRNA vaccines improve by an order of magnitude, making mRNA vaccines cost-competitive with conventional protein subunit vaccines for global health applications.